{"aliases":[{"type":"Synonym","name":"androgen receptor antagonist ARN-509"},{"type":"CodeName","name":"ARN-509"},{"type":"Abbreviation","name":"AR antagonist ARN-509"},{"type":"USBrandName","name":"Erleada"},{"type":"CodeName","name":"JNJ-56021927"},{"type":"CASRegistryName","name":"956104-40-8"},{"type":"ChemicalStructureName","name":"4-(7-(6-cyano-5-(trifluoromethyl)pyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro(3.4)octan-5-yl)-2-fluoro-N-methylbenzamide"},{"type":"CodeName","name":"ARN 509"},{"type":"CodeName","name":"ARN509"},{"type":"CodeName","name":"JNJ 56021927"}],"definition":{"html":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","text":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/apalutamide","text":"Apalutamide"},"nciConceptId":"C92574","nciConceptName":"Apalutamide","termId":683082,"name":"apalutamide","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"apalutamide"}